News and Updates

FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.

FDA announced seven recent warning letters sent to companies for illegally marketing products containing 7-hydroxymitragynine, also known as 7-OH.

FTC is sending payments totaling more than $409,000 to consumers who purchased weight-loss supplements that were deceptively marketed.

Professional development and education opportunity. 

FDA has become aware of reports of adverse events involving compounded topical finasteride products.

Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies, according to FDA. 

Summary of changes to WADA Prohibited List